Denali Therapeutics earnings set the tone for investors

Denali Therapeutics (DNLI) reported second quarter 2026 revenue of US$3.6 million, with a net loss of US$127.55 million and basic loss per share from continuing operations of US$0.68.

Denali Therapeutics shares currently trade at US$24.40, with a 90 day share price return of 34.73% and a year to date share price return of 49.97%. The 1 year total shareholder return of 64.64% contrasts with a 5 year total shareholder return that is still down 52.81%. This suggests recent momentum has picked up from a weaker long term base as investors react to the latest earnings update.

If Denali Therapeutics has you watching the biotech space more closely, it can help to see what else is moving. Take a look at 41 healthcare AI stocks.

After a sharp move in Denali Therapeutics shares and a wide gap between the current US$24.40 price and analyst and intrinsic value estimates, it is worth asking where fair value really sits. The next section breaks that down.

Most Popular Narrative: 41.9% Undervalued

Denali Therapeutics closed at $24.40 while the most followed narrative sets fair value at $42.00, which frames the recent share price strength in a different light.

The first full commercial quarter of AVLAYAH, with US$3.6 million in net product revenue and early coverage for more than 50% of commercial lives, points to an expanding rare disease franchise that can increase revenue as more eligible Hunter syndrome patients start therapy.

Want to see how a rare disease launch, a broad brain delivery platform, and ambitious revenue and margin targets all feed into that higher fair value? The narrative leans on aggressive growth curves, rising profitability, and a rich future earnings multiple that stands well above typical biotech assumptions.

Result: Fair Value of $42.00 (UNDERVALUED)

However, Denali Therapeutics still faces key risks related to its heavy reliance on AVLAYAH and the uncertain clinical and regulatory path for its broader transport vehicle pipeline.

Another View on Denali Therapeutics valuation

The bullish narrative casts Denali Therapeutics as 41.9% undervalued at $42.00. Our DCF model points in the opposite direction. It estimates future cash flows at just $3.73 per share, which implies the current $24.40 price is expensive rather than cheap. Which signal do you trust more: sentiment or cash flow math?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Denali Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 52 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals around Denali Therapeutics, this is a moment to move quickly and evaluate how the story aligns with your own risk and reward balance. To see how those concerns and positives compare side by side, review the 2 key rewards and 2 important warning signs

Looking for more Denali Therapeutics sized opportunities?

If Denali Therapeutics has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to uncover fresh stock ideas that might suit your goals next.

• Target steadier candidates by reviewing companies in the 80 resilient stocks with low risk scores that may better align with a cautious approach.
• Hunt for potential mispriced opportunities through the screener containing 19 high quality undiscovered gems and see which stocks the market may not be paying attention to yet.
• Strengthen your watchlist by checking the solid balance sheet and fundamentals stocks screener (50 results) for businesses that pair financial resilience with ongoing fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.